Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameKanghua Health
Stock Code03689
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities專注於透過多學科私立營利性綜合醫院向病人提供連續醫療服務,包括住院醫療服務、門診醫療服務及體檢,主要於廣東省東莞經營康華醫院及仁康醫院。
Listing Date2016-11-08
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國廣東省東莞市東莞大道1000號
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitekanghuagp.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 11.60 / shares
Offer Price RangeTo be extracted
Lot Size200 shares
Entry ThresholdTo be extracted
Par ValueRMB 1.0 / shares
Offer Period2016-10-27 to 2016-11-01
Global Offering Shares84,000,000 shares
HK Public Offer Shares (Initial)8,400,000 shares (10.0%)
Public Offer Lots (Initial)42,000lots (Pool A21,000lots,Pool B21,000lots)
International Placing Shares (Initial)75,600,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO334,000,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share5.3%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 974,400,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 151.1M
Est. Threshold HK$ 9.71B
Analysis Result HK market cap below threshold, need +6330%

Valuation & Financials

Market Cap (at Offer Price)HK$ 4,358,700,000
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status截至2015年12月31日止年度盈利約人民幣118.9百萬元
Period-End Cash Balance人民幣95.5百萬元
Listing Expenses~HK$ 91,600,000
Listing Expenses / Funds Raised~9.4%
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 2013201420152016-04
Revenue 858,874985,1081,063,702380,121
Cost of sales -669,778-761,424-824,290-300,020
Gross profit 189,096223,684239,41280,101
Other income and gains, net 66,33870,49264,30110,097
Administrative expenses -74,365-79,855-83,657-30,454
Operating profit 178,868212,107215,97159,278
Net finance costs -54,126-76,895-67,153-5,142
Profit before tax 124,742135,212148,81854,136
Income tax expense -15,629-27,445-29,854-14,414
Profit for the year 109,113107,767118,96439,722
Profit attributable to owners 107,309102,237118,84740,063
Balance Sheet
Item 2013201420152016-04
Cash and cash equivalents 45,93937,34695,52068,049
Trade and bills receivables 69,60759,35788,217111,502
Inventories 35,72133,67238,19544,339
Total current assets 671,714664,816775,115706,826
Total assets 1,821,5981,885,0241,105,9201,043,867
Total current liabilities 1,738,1501,746,656859,172757,397
Total liabilities 1,738,1501,746,656859,172757,397
Total equity 83,448138,368246,748286,470
Equity attributable to owners 73,894123,284231,547271,610
Interest-bearing borrowings 748,000918,500341,800213,400
Cash Flow Statement
Item 2013201420152016-04
Net cash from operating activities 213,634205,951198,90258,801
Net cash from investing activities -379,279-118,752872,76056,377
Net cash from financing activities 179,118-95,792-1,013,488-142,649
Net increase in cash 13,473-8,59358,174-27,471
Depreciation of PP&E 39,98837,64638,95213,659
Purchase of PP&E -34,601-18,156-86,036-14,717
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 10.6
First Day OpenHK$ 11.5
First Day Change-8.62%
First Day Volume11178400.0
First Day Turnover120905000.0
Use of Proceeds
1、約90.4百萬港元 (或所得款項凈額9%)將用于擴大及增加康華醫院及仁康醫院現有的醫療保健服務; 2、約361.6百萬港元(或所得款項凈額36%)將用于擴大我們在多學科專業治療及診斷方面的營運能力以及多學科專業治療及診斷的能力以及升級康華醫院及仁康醫院的醫療設施; 3、約100.5百萬港元(或所得款項凈額10%)將用于與中國的第三方醫院擴展我們醫院的咨詢及管理業務; 4、約351.6百萬港元(或所得款項凈額35%)將用于擴展我們在中國的醫療保健業務,包括透過選擇性并購其他醫院; 5、約100.5百萬港元(或所得款項凈額10%)將撥作營運資金及作其他一般企業用途。

Underwriting Syndicate

Sole Sponsor (1)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
Overall Coordinators (1)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
Joint Bookrunners (4)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 招银国际融资有限公司 CE AVM940 农银国际融资有限公司 CE AWL249 交银国际证券有限公司 CE APJ121
Joint Lead Managers (5)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 招银国际融资有限公司 CE AVM940 农银国际融资有限公司 CE AWL249 交银国际证券有限公司 CE APJ121 Zhaobangji International Capital Limited CE BFS892

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 升鹏有限公司 206,897,600 HKD — 5.34% — 6 months 2017-05-08

Directors & Management

PositionChinese nameEnglish Name
Chairman王君揚—
Company Secretary黃偉囱、周慶齡—
No director data available.

Major Shareholders

Major Shareholders & Holdings王君揚、王愛慈、陳旺枝及王愛勤為控股股東(一致行動人士),通過康華集團、興業集團及興達物業合共持有250,000,000股內資股,緊隨全球發售後約佔74.85%(假設超額配股權未獲行使)。
About this page

This page shows Kanghua Health (03689) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect